Abrocitinib Medicine 05 December 2023 Extended indication Extension of indication to include treatment of adolescents 12 to < 18 years of age with moderate to severe atopic dermatitis Therapeutic value No estimate possible yet Total cost Registration phase Registration application pending Product Active substance Abrocitinib Domain Chronic immune diseases Reason of inclusion Indication extension IND Main indication Skin diseases Extended indication Extension of indication to include treatment of adolescents 12 to < 18 years of age with moderate to severe atopic dermatitis Current proprietary name Already available biosimilars / generics Proprietary name Cibinqo Manufacturer Pfizer Portfolio holder Mechanism of action JAK tyrosine kinase inhibitor Route of administration Oral Therapeutical formulation Tablet Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP Unknown Submission date June 2023 Expected Registration April 2024 Orphan drug No Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks